Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting.
Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting.
复制标题
DOI：
10.7150/jca.16901
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Hielscher A
中科院分区：
文献类型：
--
作者：
Wang JP;Hielscher A
纤连蛋白是一种基质糖蛋白，它不仅被发现在几种癌症中过表达，而且已被证明参与肿瘤发生的几个步骤。本文就纤维连接蛋白的异常表达对肿瘤生长、侵袭、转移及耐药的影响作一综述。特别是，这次审查将集中在细胞受体配体和纤连蛋白之间的相互作用，以及这种相互作用如何影响下游信号事件，帮助肿瘤的进展。这篇综述将进一步讨论针对纤连蛋白和/或与纤连蛋白的细胞相互作用的治疗药物的可能影响，并将另外讨论新的方法，通过该方法来限制肿瘤内和肿瘤外纤连蛋白的表达和导致纤连蛋白异常表达的细胞事件。预计这些研究将为未来的研究奠定基础，不仅有助于理解纤连蛋白及其预后意义，而且还将进一步阐明治疗的新靶点。
Fibronectin is a matrix glycoprotein which has not only been found to be over-expressed in several cancers, but has been shown to participate in several steps of tumorigenesis. The purpose of this review is to illustrate how aberrant fibronectin expression influences tumor growth, invasion, metastasis and therapy resistance. In particular, this review will focus on the interactions between cell receptor ligands and fibronectin and how this interaction influences downstream signaling events that aid tumor progression. This review will further discuss the possible implications of therapeutic drugs directed against fibronectin and/or cellular interactions with fibronectin and will additionally discuss novel approaches by which to limit intra- and extra-tumoral fibronectin expression and the cellular events which lead to aberrant fibronectin expression. It is anticipated that these studies will set a basis for future research that will not only aid understanding of fibronectin and its prognostic significance, but will further elucidate novel targets for therapeutics.